CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models. Brinkmann BJ, Floerchinger A, Schniederjohann C, Roider T, et al. Blood 2024 May 28:blood.2023022682. doi: 10.1182/blood.2023022682.

Read + Share

Amedeo Smart

Independent Medical Education

Brinkmann BJ, Floerchinger A, Schniederjohann C, Roider T, et al. CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models. Blood 2024 May 28:blood.2023022682. doi: 10.1182/blood.2023022682.
PMID: 38805637